Fig. 8: Inhibition of RAF/MEK and FAK show substantial activity in controlling the growth of Rac1 P29S-mutant cells.
From: A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition
A 1 ×106 A375 Rac1 P29S cells were implanted subcutaneously in the left and right flanks of 15 female nude mice (total of 30 tumors at the outset of the experiment). As average tumor volumes reached 100 mm3, mice were randomized and treated starting 1 week after randomization with vehicle control (5 mice) or avutometinib plus the FAK inhibitor VS-4718 (10 mice; treatment day 0 as indicated with the dashed line). Avutometinib/VS-4718 significantly controlled Rac1 P29S tumor growth, ****P < 0.0001 Mann–Whitney U test as measured on treatment day 7. B Kaplan–Meier analysis of survival of mice treated with vehicle control or avutometinib plus VS-4718. The drug combination significantly prolonged survival (P < 0.0001, Mantel–Cox log rank test).
